Health

  • June 02, 2026

    Pharma Co. Inks $7M Deal To End Investor's Cancer Study Suit

    A Spectrum Pharmaceuticals Inc. investor has asked a New York federal court to approve a $7 million deal resolving class action claims alleging the drugmaker overstated its regulatory prospects for winning approval for a cancer treatment.

  • June 02, 2026

    FTC Orders Ascension Divestiture To Complete $3.9B Deal

    Nonprofit health system Ascension Health Alliance must divest several of its surgery center facilities in order to complete its proposed $3.9 billion acquisition of AmSurg LLC, the Federal Trade Commission said Tuesday.

  • June 02, 2026

    Mich. Firm Says Insurer Can't Avoid Bad Faith Counterclaim

    A Michigan law firm urged a federal court not to toss a counterclaim alleging that its professional liability insurer handled the firm's bid for coverage of an underlying malpractice suit in bad faith, saying the claim properly seeks declaratory relief under the state's insurance code.

  • June 01, 2026

    Albertsons Had Duty To Curb Opioid Diversion, Judge Rules

    As providers of controlled substances, pharmacy giants Albertsons and Safeway had legal duties to prevent the diversion of opioid drugs, a Washington state judge ruled on Monday, though whether the companies failed to fulfill those duties will be determined at trial.

  • June 01, 2026

    DC Circ. Says Military Trans Ban Flouts Constitutional Rights

    A divided D.C. Circuit panel Monday said the Trump administration illegally banned transgender individuals from military service, then narrowed a preliminary injunction to prevent the government's exclusion of transgender people presently serving in the military but not those desiring to enlist.

  • June 01, 2026

    Jones Day Adds Former SDNY Civil Frauds Unit Co-Chief

    Jacob Bergman, the former co-chief of the Southern District of New York's Civil Frauds Unit, has joined Jones Day as a partner in the firm's healthcare and life sciences practice group in New York, according to a Monday announcement.

  • June 01, 2026

    Abbott Labs Spinal Cord Device Causes Shocks, Suit Claims

    A New Jersey man said in a suit filed in Garden State federal court on Friday that Abbott Laboratories' spinal cord stimulator system was manufactured with defects that were never truly resolved because of Abbott's mischaracterization of the issue, which caused him painful electric shocks.

  • June 01, 2026

    11th Circ. Won't Stop Joint Hearing In Depo-Provera MDL

    A group of Delaware plaintiffs who say Pfizer's hormonal contraceptive Depo-Provera causes brain tumors can't block a joint evidentiary hearing with a Florida federal court overseeing multidistrict litigation over the same claims after the Eleventh Circuit denied their petition Monday.

  • June 01, 2026

    DOJ Says Ohio Health System Can't Duck Antitrust Case

    The U.S. Department of Justice defended its antitrust case accusing OhioHealth Corp. of blocking competition through its contracts with insurers, telling an Ohio federal court the health system is depriving consumers of lower-cost health plans.

  • June 01, 2026

    Judge Trims Dental Patent Case, But Keeps Patent Alive

    A Delaware federal judge has refused to invalidate a pair of dental patents that medical technology companies Align Technology and Medit Corp. were accused of infringing, but did agree to narrow the case.

  • June 01, 2026

    Plaintiffs' Counsel In Tylenol MDL Agree To $50K Donation

    A plaintiffs' attorney and law firm sanctioned in multidistrict litigation alleging prenatal exposure to acetaminophen can cause autism agreed to donate $50,000 to maternal health organization March of Dimes in lieu of paying attorney fees, according to a letter filed Monday in New York federal court. 

  • June 01, 2026

    NFL Benefit Plans Vow To Reset 'Race Norming' Test Scores

    The NFL's disability and retirement plans have agreed to reassess former players' cognitive health to settle a sweeping class action accusing the plans of muting the results based on race.

  • June 01, 2026

    Conn. Alters Pot Tax, Gives Cities Aid To Cut Property Taxes

    Connecticut will change its cannabis tax structure, provide funding to local governments for property tax reductions and make other tax changes under a 2027 budget bill signed by the governor.

  • June 01, 2026

    Insurer Says No Coverage For Va. Medicaid Billing Row

    An Argo Group unit told a Virginia federal court it isn't on the hook for two suits alleging a provider of therapeutic services for children and adolescents cheated Medicaid out of millions of dollars and transferred assets to avoid paying creditors.

  • June 01, 2026

    NC Biz Court Bulletin: Referee Tapped, CEO To Be Deposed

    The North Carolina Business Court rounded out May by appointing a discovery referee in a healthcare antitrust class action and ordering the deposition of a top executive in a trade secrets battle, in addition to fielding a new complaint alleging unpaid capital contributions for a captive insurance company.

  • June 01, 2026

    La. Sends Psychedelic Therapy Research Bill To Governor

    Louisiana lawmakers have given final approval to a bill to establish a psychedelic-assisted therapy program under the state's health department.

  • June 01, 2026

    TriZetto, Infosys Fight Each Side's CEO Deposition Bids

    Cognizant TriZetto Software Group and Infosys Ltd. have filed dueling motions to block depositions of each other's top executives in a trade secret lawsuit over allegations that Infosys misused confidential access to TriZetto's healthcare software to build competing products.

  • June 01, 2026

    Epstein Becker Adds 6 Manatt Phelps Litigators

    Epstein Becker Green has added six litigators experienced in commercial and healthcare matters who previously worked for Manatt Phelps & Phillips LLP in its Los Angeles, Chicago and Washington, D.C., offices, the firm announced Monday.

  • June 01, 2026

    Abortion Protester Denied 2nd Shot At Jury Trial In 4th Circ.

    The Fourth Circuit has decided not to rehear an appeal over whether a South Carolina abortion protestor should be given a new trial after the court previously affirmed his conviction for blocking the doors of a clinic.

  • June 01, 2026

    High Court Turns Away Health Workers' Vaccine Mandate Case

    The U.S. Supreme Court declined a bid for review Monday from workers who said a nonprofit healthcare system and Washington state violated their rights by issuing COVID-19 vaccination mandates, leaving in place a Ninth Circuit ruling that said their case didn't pass muster.

  • June 01, 2026

    Justices Skip CareDx's Bid To Revive $45M False Ad Award

    The U.S. Supreme Court on Monday declined to take up a challenge to a Third Circuit decision that wiped out a nearly $45 million false advertising award against Natera Inc., preserving a ruling that said proof of actual consumer deception is required to support damages.

  • May 29, 2026

    Fla. Panel Upholds Reduced $4M Car Crash Verdict

    A Florida appeals court Friday affirmed the reduction of a $2 million medical expenses award as part of a $4.7 million verdict in an auto collision case to about $1.3 million, saying the cost of certain future medical procedures was based on speculation rather than sufficient evidence.

  • May 29, 2026

    Telehealth Co. Hims Likely To Get Suicide Suit Trimmed

    A Washington state judge indicated Friday that he'll narrow a family's lawsuit blaming a 19-year-old's suicide on allegedly subpar mental health treatment he received through telehealth company Hims & Hers and its partner businesses, saying he'll nix corporate negligence claims and free online pharmacy XeCare from the case.

  • May 29, 2026

    Illumina Ducks DNA Sequence Rival's Antitrust Suit, For Now

    A DNA sequencing startup will have to rejigger its antitrust lawsuit against Illumina after a California federal judge said it hasn't shown that the industry giant has entered exclusive agreements and hasn't adequately asserted that Illumina priced its offerings below cost, among other failings.

  • May 29, 2026

    Joint Venture Can't Claim Small Biz Status, Judge Finds

    A U.S. Court of Federal Claims judge said a joint venture can't upend the U.S. Small Business Administration's determination that it didn't qualify as a small business for a defense contract solicitation because its mentor-protégé agreement fizzled before the final proposal deadline. 

Expert Analysis

  • 2 AI Snafus Show Why Attys Can't Outsource Judgment

    Author Photo

    The recent incident involving Sullivan & Cromwell where citations in a filed motion were fabricated by artificial intelligence, as well as a punitive ruling from the Sixth Circuit in U.S. v. Farris, demonstrate that the obligation to supervise AI has belonged and always will belong to lawyers, says John Powell at the Kentucky School Boards Association.

  • NY Opioid Antagonist Mandate Leaves Employers Guessing

    Author Photo

    A recently enacted New York law will require employers that are federally mandated to maintain first-aid supplies to now include an opioid antagonist, but being that it is subject to a complicated Occupational Safety and Health Administration analysis, employers face several unanswered compliance questions, say attorneys at Conn Maciel.

  • Calif. Case Raises Questions For Medical Practice Investors

    Author Photo

    The California attorney general's amicus brief in Art Center v. WCE and the California Medical Association's response highlight how the California appeals court's ruling could significantly affect the structure and enforceability of succession arrangements in medical practice ownership, say attorneys at Ropes & Gray.

  • Previewing FDA Preapproval Access In Psychedelics EO

    Author Photo

    The second of two pathways for psychedelic drug access outlined in President Donald Trump's recent executive order constitutes an unprecedented expansion of the Right to Try Act, which could fundamentally alter the psychedelic access landscape while presenting significant regulatory, operational and legal challenges, say attorneys at Husch Blackwell.

  • Previewing FDA National Priority Vouchers In Psychedelics EO

    Author Photo

    President Donald Trump's recent executive order on psychedelic drug access represents a watershed moment in federal drug policy, but its significance lies in two distinct regulatory pathways, the first being the Commissioner's National Priority Vouchers, which offer a significant opportunity to compress U.S. Food and Drug Administration review, say Kimberly Chew at Husch Blackwell and Odette Hauke at Odette Alina.

  • Series

    Playing Magic: The Gathering Makes Me A Better Lawyer

    Author Photo

    The competitive card game Magic: The Gathering offers me a training ground for the strategic thinking skills crucial to litigation, challenging me to adapt to oft-updated rules, analyze text as complicated as any statute and anticipate my opponent’s next moves, says Christopher Smith at Lash Goldberg.

  • Why Product-Based Public Nuisance Claims May Be Waning

    Author Photo

    The Maryland Supreme Court's recent decision in Express Scripts v. Anne Arundel County is the latest in a national trend of rulings rejecting product-based public nuisance claims — but other forms of government litigation against companies that allegedly increase the cost of public services are likely to continue, say attorneys at Simpson Thacher.

  • What's At Stake For Employers In Fight Over Visa Pause

    Author Photo

    For employers that rely on foreign talent, the Trump administration’s suspension of immigrant visa issuance for the nationals of 75 countries is creating practical problems, and a recently filed lawsuit challenging the pause could determine whether consular processing, for some, ceases to be an individualized process, says attorney Lisa Eisenberg.

  • Improving Well-Being In Law, 10 Years After Landmark Study

    Author Photo

    An important 2016 study revealed significant substance abuse and mental health issues among lawyers, and while the findings helped normalize the conversation around these topics, a decade later, structural change is still needed, says Denise Robinson at PLI.

  • How To Gear Up For Trump's Pharma Tariffs

    Author Photo

    President Donald Trump's proclamation establishing tariffs on certain pharmaceutical products holds a few areas of ambiguity that companies should review and prepare for before the tariffs come into effect later this year, say attorneys at Arnold & Porter.

  • AG Watch: Texas Charts A Course On Investigative Authority

    Author Photo

    The Texas Supreme Court's recent decision in Texas v. PFLAG affirmed, and arguably expanded, the Texas attorney general's civil investigative demand authority, providing a road map that other courts evaluating state attorney general CIDs may find instructive, amid a lack of precedent, say attorneys at Kelley Drye.

  • Initial Virginia AG Actions Signal Focus On Multistate Efforts

    Author Photo

    Now that Virginia Attorney General Jay Jones has reached the 100-day mark in office, his first set of actions reveals a clear preference for coalition with regional and national counterparts, which means the primary risk for businesses is no longer just the fact of enforcement, but the speed at which investigations can escalate, says Lauren Cooper at Hogan Lovells.

  • How CMS Fraud Priorities Complicate Provider Acquisitions

    Author Photo

    As the Centers for Medicare & Medicaid Services steps up usage of its affiliates authority and post-transaction audits, parties contemplating the acquisition or sale of home health and hospice providers should take steps to avoid the potential suspension of Medicare billing privileges, say attorneys at Alston & Bird.

  • Mapping Philly US Atty's White Collar Enforcement Push

    Author Photo

    Attorneys at Blank Rome discuss the U.S. Attorney for the Eastern District of Pennsylvania David Metcalf’s commitments and priorities, survey early results from his first year, and suggest practical action items for companies operating under the office's jurisdiction.

  • How The Coming Months Will Shape State Drug Price Boards

    Author Photo

    The future of state prescription drug affordability boards may be determined in the next few months, between an upcoming court decision in a challenge against state authority to set drug prices, and pending state decisions about whether to use federal Medicare maximum fair prices as reference, say Michael Kolber, Steven Chen and Kelechi Ezealaji at Manatt.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Health archive.